98%
921
2 minutes
20
Objective: To study the value of amino-terminal pro-brain natriuretic peptide (NT-proBNP) in predicting symptomatic patent ductus arteriosus (sPDA) in preterm infants.
Methods: Preterm infants born at a gestational age (GA) of ≤ 32 weeks and diagnosed with patent ductus arteriosus (PDA) by echocardiography within 48 hours after birth between June 2014 and April 2015 were selected as subjects. Their clinical manifestations were observed, and serum NT-proBNP levels were measured and echocardiography was performed at 3 and 5 days after birth. The infants were divided into sPDA group and asymptomatic PDA (asPDA) group based on their clinical manifestations and the results of echocardiography. The correlations between serum NT-proBNP level and echocardiographic indices were analyzed. Serum NT-proBNP levels were compared between the two groups. The receiver operator characteristic (ROC) curve was applied to determine the sensitivity and specificity of serum NT-proBNP in the prediction of sPDA.
Results: A total of 69 preterm infants were enrolled in this study, with 13 infants in the sPDA group and 56 infants in the asPDA group. Serum NT-proBNP level was positively correlated with the diameter of the arterial duct (r=0.856; P<0.05)and the ratio of left atrial diameter to aortic root diameter (LA/AO) (r=0.713; P<0.05). At 3 and 5 days after birth, the serum NT-proBNP levels in the sPDA group were significantly higher than those in the asPDA group (P<0.05). The area under the ROC curve (AUC) for the prediction of sPDA by NT-proBNP levels at 3 days after birth was 0.949 (95% CI: 0.892-1.000; P<0.001), with a cut-off value of 27 035 pg/mL (sensitivity: 92.3%; specificity: 94.6%); the AUC for the prediction of sPDA by NT-proBNP levels at 5 days after birth was 0.924 (95% CI: 0.848-1.000; P<0.001), with a cut-off value of 6 411 pg/mL (sensitivity: 92.3%; specificity: 92.9%).
Conclusions: NT-proBNP may be a quantitative index for shunt volume. The measurement of serum NT-proBNP levels on 3 and 5 days after birth may be useful to predict sPDA in preterm infants.
Download full-text PDF |
Source |
---|
Ethnopharmacological Relevance: Heart failure (HF), the terminal stage of various cardiovascular diseases, represents a significant threat to global health. Fuxin Decoction (FXD), a classical Traditional Chinese Medicine (TCM) formula, has demonstrated therapeutic efficacy in HF treatment. However, its bioactive components and precise mechanisms remain to be elucidated.
View Article and Find Full Text PDFEur Heart J Open
September 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Aims: Intravenous tolvaptan sodium phosphate (IV-tolvaptan) is a novel aquaretic agent for acute decompensated heart failure (ADHF). This study evaluated its short-term effects and prognostic implications in clinical practice.
Methods And Results: In this retrospective cohort of 169 consecutive ADHF patients receiving IV-tolvaptan for the first time (mean age 76.
Front Cardiovasc Med
August 2025
Department of Cardiology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.
Background: Acute myocardial infarction in the elderly often leads to significant left ventricular structural remodeling, which adversely affects prognosis. This study aims to evaluate the effects of intensive rosuvastatin therapy on markers of ventricular remodeling and cardiac function following percutaneous coronary intervention (PCI) in elderly patients with ST-segment elevation myocardial infarction (STEMI).
Methods: This study enrolled 100 patients aged ≥60 years with STEMI who underwent emergency PCI.
ESC Heart Fail
September 2025
Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Aims: The diagnosis of peripartum cardiomyopathy (PPCM) is often delayed due to the absence of disease-specific biomarkers. Recently, serum proteins-QSOX1, adiponectin (ADIPOQ) and ITIH3-have shown potential for improving diagnostic accuracy, especially when used with NT-proBNP. However, the influence of ethnicity on their expression remains unclear.
View Article and Find Full Text PDFAm J Cardiol
September 2025
Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Background: While trial evidence supports the benefit of angiotensin receptor-neprilysin inhibitor (ARNI) therapy in heart failure with reduced ejection fraction (HFrEF), its effectiveness in routine clinical practice is less explored. This study investigated the relative and absolute effectiveness of ARNI in patients with HFrEF.
Methods: This nationwide Danish database study included patients with left ventricular ejection fraction (LVEF) ≤40%, 2018-2023.